Fortress Biotech Inc(FBIO) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Fortress Biotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel pharmaceutical and biotechnology products. The company is headquartered in New York City, New York and currently employs 88 full-time employees. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies. Fortress has 11 operating subsidiaries that include: 4 commercial stage programs, 25 development stage programs, targeting 6 therapeutic areas: Immuno-oncology, Hematology, Gene Therapy, Pain Management, Rare Diseases and Dermatology. In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies. Fortress subsidiaries include Aevitas Therapeutics, Avenue Therapeutics, Caelum Biosciences, Cellvation, Inc., Checkpoint Therapeutics, Cyprium Therapeutics, Helocyte, Inc., Journey Medical Corporation, Mustang Bio and Tamid Bio, Inc.

Current Price

$3.94

RSI

34.244

Beta:

2.440706

June 30, 2020
91.3M
-18.5M

2.238 %
33.782 %
-3.577 %
-51.657 %

$36,629,000
$26,882,000
$187,584,000
$16,480,000
$-621,000
$0
36.258 %
-597.805 %
1038.252 %
103.768 %
0.000 %

$-101,660,000
$-130,800,000
$-65,363,000
$-55,168,000
$-72,128,000
$-20,386,000
28.664 %
-50.028 %
-15.598 %
30.742 %
-71.736 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.